ライフサイエンスコーパス: rheumatoid arthritis

1 ectal carcinoma), and an autoimmune disease (rheumatoid arthritis).

2 sorders (e.g., systemic lupus erythematosus, rheumatoid arthritis).

3 ultiple sclerosis, sarcoidosis, and juvenile rheumatoid arthritis).

4 synoviocytes contributes to joint damage in rheumatoid arthritis.

5 eukin-6 (IL-6) in inflammatory diseases like rheumatoid arthritis.

6 type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis.

7 ular disease and exert beneficial actions in rheumatoid arthritis.

8 diabetes, systemic lupus erythematosus, and rheumatoid arthritis.

9 , allergic asthma, autoimmune nephritis, and rheumatoid arthritis.

10 Janus kinase inhibitor for the treatment of rheumatoid arthritis.

11 )CD4(+) T cells in synovium of patients with rheumatoid arthritis.

12 mmatory networks that subserve diseases like rheumatoid arthritis.

13 potential therapeutic target for suppressing rheumatoid arthritis.

14 damage in murine models of inflammatory and rheumatoid arthritis.

15 ty of chronic inflammatory diseases, such as rheumatoid arthritis.

16 mune diseases, including type 1 diabetes and rheumatoid arthritis.

17 ent of autoimmune diseases such as lupus and rheumatoid arthritis.

18 s together with unmet needs of patients with rheumatoid arthritis.

19 thological conditions, such as pregnancy and rheumatoid arthritis.

20 in biological-treatment naive patients with rheumatoid arthritis.

21 file and is efficacious in a rodent model of rheumatoid arthritis.

22 nse, leukaemia, age-related hearing loss and rheumatoid arthritis.

23 rophage-driven inflammatory diseases such as rheumatoid arthritis.

24 se, autoimmune thyroid disease, and juvenile rheumatoid arthritis.

25 T cell dysregulation as a central problem in rheumatoid arthritis.

26 usceptibility to autoimmune disease, notably rheumatoid arthritis.

27 syndromes, such as cardiovascular disease or rheumatoid arthritis.

28 plex (MHC) across all three study cohorts of rheumatoid arthritis.

29 rrelated in joint synovia from patients with rheumatoid arthritis.

30 of these IgGs can be used as biomarkers for rheumatoid arthritis.

31 t target these molecules in diseases such as rheumatoid arthritis.

32 is associated with the inflammatory state of rheumatoid arthritis.

33 ies including hematological malignancies and rheumatoid arthritis.

34 nd the life expectancy of many patients with rheumatoid arthritis.

35 mpound that entered into clinical trials for rheumatoid arthritis.

36 rders such as inflammatory bowel disease and rheumatoid arthritis.

37 for allergy, atopic dermatitis, asthma, and rheumatoid arthritis.

38 or (uPAR) in joint tissue from patients with rheumatoid arthritis.

39 raits, such as the interleukin-27 pathway in rheumatoid arthritis.

40 esis of BI 653048, a compound active against rheumatoid arthritis.

41 orted nursing interventions in patients with rheumatoid arthritis.

42 factor alpha blocker currently used to treat rheumatoid arthritis.

43 lammatory bowel disease, Crohn's disease and rheumatoid arthritis.

44 eported after IL-6 blockade in patients with rheumatoid arthritis.

45 nt or clinical use for indications including rheumatoid arthritis.

46 , including systemic lupus erythematosus and rheumatoid arthritis.

47 ases, including cancer, atherosclerosis, and rheumatoid arthritis.

48 D1 expression with decreased bone erosion in rheumatoid arthritis.

49 t predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infectio

50 Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]

51 ; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammator

52 We included 16 studies (9 of patients with rheumatoid arthritis, 8 of patients with inflammatory bo

53 d T cells in joint tissue from patients with rheumatoid arthritis, a chronic immune-mediated arthriti

54 , we identified largest-ever effect on Asian rheumatoid arthritis across human non-HLA regions at GTF

55 .8; 95% confidence interval [CI] = 1.2-2.5), rheumatoid arthritis (adjusted OR = 1.7; 95% CI = 1.5-1.

56 gible participants were patients with active rheumatoid arthritis aged at least 18 years, with four o

57 ted the hypothesis that patients with active rheumatoid arthritis also have carotid plaque inflammati

58 en periodontitis and cardiovascular disease, rheumatoid arthritis, Alzheimer's disease, pulmonary dis

59 In patients with rheumatoid arthritis and an inadequate response to biolo

60 enrolled patients with active, seropositive rheumatoid arthritis and an inadequate response to synth

61 in the inflamed synovium from patients with rheumatoid arthritis and compared with synovium from hea

62 ssociated with inflammatory diseases such as rheumatoid arthritis and Crohn's disease.

63 inical investigations and clinical trials in rheumatoid arthritis and follicular lymphoma.

64 lammatory reflex to significantly ameliorate rheumatoid arthritis and inflammatory bowel disease prov

65 eases such as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), me

66 of-concept is established for immune-related rheumatoid arthritis and inflammatory bowel disease, as

67 various inflammatory disease models, such as rheumatoid arthritis and inflammatory bowel disease.

68 ity, and deregulated PGRN is associated with rheumatoid arthritis and inflammatory bowel disease.

69 e IL-6 pathway, has been approved for use in rheumatoid arthritis and interest in transplantation has

70 improve other autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

71 bitor treatment in patients seropositive for rheumatoid arthritis and naive to treatment with biologi

72 y, is under development for the treatment of rheumatoid arthritis and other diseases.

73 eting IL-20 is effective in the treatment of rheumatoid arthritis and psoriasis, both with strong GWA

74 he genetic overlap observed between PTSD and rheumatoid arthritis and psoriasis.

75 nically approved agents for the treatment of rheumatoid arthritis and renal transplantation, respecti

76 Apoptotic CD4(+) T cells from patients with rheumatoid arthritis and systemic lupus erythematosus we

77 viously been implicated in severity of human rheumatoid arthritis and systemic lupus erythematosus, i

78 nd, more common autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, s

79 ts who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascula

80 of pleiotropy was observed between PTSD and rheumatoid arthritis and, to a lesser extent, psoriasis.

81 Search terms included "biologics", "rheumatoid arthritis" and their synonyms.

82 o systemic (systemic lupus erythematosus and rheumatoid arthritis) and two organ-specific (multiple s

83 re profoundly protected in several models of rheumatoid arthritis, and Ab blockade of G-CSF also prot

84 onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.

85 act of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating monogenic disorder

86 infections, allergies, autoimmune diseases, rheumatoid arthritis, and inflammatory bowel disease.

87 this system has been noted in patients with rheumatoid arthritis, and its pathogenic role has been c

88 seases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis.

89 teers, phase 3 trials involved patients with rheumatoid arthritis, and observational studies involved

90 tension, cognitive function, kidney disease, rheumatoid arthritis, and quality of life.

91 plied our method to data on gene expression, rheumatoid arthritis, and type 2 diabetes and overwhelmi

92 in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

93 therapies, however, which are effective for rheumatoid arthritis, are either ineffective for psorias

94 nective tissue diseases (CTD) like lupus and rheumatoid arthritis associate with cardiovascular risk,

95 Comparison groups included patients with rheumatoid arthritis-associated ILD (RA-ILD; n = 33), pa

96 l-length sgp130 and the shorter forms sgp130-rheumatoid arthritis-associated peptide (RAPS) and sgp13

97 This disease network portraits rheumatoid arthritis, asthma, atherosclerosis, pulmonary

98 e aged 18 years or older with a diagnosis of rheumatoid arthritis at screening, as defined by the 201

99 control of inflammation optimise outcomes in rheumatoid arthritis but these approaches have not yet b

100 characterized in autoimmune disorders (e.g., rheumatoid arthritis), but there are some exceptional lo

101 n are highly effective treatments for active rheumatoid arthritis, but so far no randomised controlle

102 ion covering gene DSC3 being associated with rheumatoid arthritis, but the GCP provides smaller P-val

103 ptides are used as biomarkers for diagnosing rheumatoid arthritis by measuring anti-citrullinated pro

104 s) and European (n = 45,790; 11 collections) rheumatoid arthritis case-control cohorts with Immunochi

105 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, and mul

106 core in 28 joints (DAS28) was calculated and rheumatoid arthritis classification criteria applied.

107 D-naive, aged 18 years or older, met current rheumatoid arthritis classification criteria, and had a

108 The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) tri

109 shock protein 90 (HSP90) are associated with rheumatoid arthritis complicated by interstitial lung di

110 pes were constructed for 213 AS cases and 46 rheumatoid arthritis controls using family data.

111 nt genetic studies in the KRN mouse model of rheumatoid arthritis demonstrate that the immunomodulato

112 ding TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are la

113 patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy.

114 es the severity of various illnesses such as rheumatoid arthritis, diabetes, and liver diseases.

115 medication (OR = 3.98; 95% CI: 2.08, 7.62), rheumatoid arthritis duration of 6-20 years (OR = 3.80;

116 channel expressed at the plasma membrane of rheumatoid arthritis fibroblast-like synoviocytes (RA-FL

117 beta1-integrin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes.

118 ons (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalgia) than those with NWU

119 es of treatment response in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndica

120 uids may lead to different diseases, such as rheumatoid arthritis, glomerulonephritis, etc.

121 le in various inflammatory diseases, such as rheumatoid arthritis, gout, sepsis, stroke, and transpla

122 applying it to Genetic Analysis Workshop 16 rheumatoid arthritis GWAS data.

123 Studies in patients with rheumatoid arthritis have shown that the rituximab biosi

124 or developing autoimmune diseases, including rheumatoid arthritis (HLA-DRB1*04).

125 Inclusion criteria were (i) patients with rheumatoid arthritis, (ii) adult population age >/=16yea

126 ess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T).

127 Rheumatoid arthritis in Agricultural Health Study spouse

128 drug or gene delivery and novel therapy for rheumatoid arthritis in an in situ forming gel formulati

129 with distinct effects on the development of rheumatoid arthritis in Asian and European populations.

130 mumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequ

131 xate combination therapy in the treatment of rheumatoid arthritis in patients with an inadequate resp

132 Patients with rheumatoid arthritis in remission exhibited high numbers

133 ed cytokines in autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, and sy

134 emonstrated to provide a therapeutic role in rheumatoid arthritis, inflammatory intestinal disease, c

135 Rheumatoid arthritis is a chronic autoimmune disease tha

136 Rheumatoid arthritis is a chronic autoimmune disorder re

137 Rheumatoid arthritis is a chronic disease that results i

138 Rheumatoid arthritis is a chronic inflammatory disease c

139 Rheumatoid arthritis is a chronic inflammatory joint dis

140 Rheumatoid arthritis is a complex disease associated wit

141 Rheumatoid arthritis is an autoimmune disease resulting

142 Rheumatoid arthritis is an autoimmune disease that is ch

143 Rheumatoid arthritis is an autoimmune disorder character

144 Rheumatoid arthritis is an autoimmune disorder that affe

145 Rheumatoid arthritis is an inflammatory condition charac

146 Rheumatoid arthritis is characterised by synovial inflam

147 to chronic autoimmune inflammation, such as rheumatoid arthritis, is ill defined and probably requir

148 c role at sites of autoimmunity, such as the rheumatoid arthritis joint where they accumulate.

149 ddison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenile idiopathic arthritis, and

150 ed CRP levels with psoriatic osteoarthritis, rheumatoid arthritis, knee osteoarthritis, systolic bloo

151 or tofacitinib's success in the treatment of rheumatoid arthritis led to biopharma's abandonment of i

152 uals, and occasionally leads to seronegative rheumatoid arthritis-like pathologies.

153 ent types of CTD were analyzed individually (rheumatoid arthritis; lupus; scleroderma; Sjogren Syndro

154 rthritis, such as ever having received daily rheumatoid arthritis medication (OR = 3.98; 95% CI: 2.08

155 ry complications contribute significantly to rheumatoid arthritis mortality.

156 ing thyroiditis, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and lupus eryt

157 ring the complex role of IL-33 in a model of rheumatoid arthritis, namely, collagen-induced arthritis

158 ontrols for five common autoimmune diseases: rheumatoid arthritis (ncases = 5,337), type 1 diabetes (

159 enous IL-1 receptor antagonist used to treat rheumatoid arthritis, normalizes hippocampal neurotransm

160 ase activity and joint damage in people with rheumatoid arthritis of the hand.

161 nd observational studies involved those with rheumatoid arthritis or inflammatory bowel disease.

162 hinese, OR = 2.35 in European Americans) and rheumatoid arthritis (OR = 1.65 in Koreans).

163 8.41), or ever having been hospitalized for rheumatoid arthritis (OR = 7.36; 95% CI: 2.95, 18.38).

164 1.27); anemia (OR, 1.19; 95% CI, 1.15-1.25); rheumatoid arthritis (OR, 1.19; 95% CI, 1.10-1.29); coag

165 .58; 95% CI, 1.51-1.66), osteoarthritis with rheumatoid arthritis (OR, 1.58; 95% CI, 1.38-1.82), anti

166 TonEBP signaling in inflammatory disease and rheumatoid arthritis pathogenesis.

167 wn to be effective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nurs

168 RvD3 was also reduced in serum from rheumatoid arthritis patients compared with healthy cont

169 e formation, while DCs from CTLA4-Ig-treated rheumatoid arthritis patients displayed diminished LC3B

170 torial staining approach to demonstrate that rheumatoid arthritis patients on therapy can mount effec

171 of platelets with synovial fluid cells from rheumatoid arthritis patients reduced inflammatory cytok

172 diovascular events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosi

173 ces to inhibit cytokines and inflammation in rheumatoid arthritis patients, and provided a mosaic vie

174 t ex-Th17 cells accumulated in the joints of rheumatoid arthritis patients.

175 pressed IL-17A production in human PBMC from rheumatoid arthritis patients.

176 w that lactate accumulates in the synovia of rheumatoid arthritis patients.

177 were suppressed in macrophages isolated from rheumatoid-arthritis patients, revealing a disease-assoc

178 portance of studying individuals at risk for rheumatoid arthritis (pre-RA) and those with early RA (e

179 nclusions and Relevance: Among patients with rheumatoid arthritis previously treated with anti-TNF dr

180 chronic conditions such as atherosclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

181 Rheumatoid arthritis (RA) affects millions world-wide.

182 From 277 patients with rheumatoid arthritis (RA) and 141 healthy individuals, w

183 tory and neurodegenerative diseases, such as rheumatoid arthritis (RA) and AD.

184 in the pathogenesis of systemic inflammatory rheumatoid arthritis (RA) and AD.

185 ible correlation of periodontal disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS

186 Rheumatoid arthritis (RA) and depression may be associat

187 ne dysfunction underlies the pathogenesis of rheumatoid arthritis (RA) and inflammatory bowel disease

188 t prevalent AD is a risk factor for incident rheumatoid arthritis (RA) and inflammatory bowel disease

189 ated TACE-mediated disease models of sepsis, rheumatoid arthritis (RA) and inflammatory bowel disease

190 e development of autoimmune diseases such as rheumatoid arthritis (RA) and is associated with the exp

191 Pain is a dominant symptom of rheumatoid arthritis (RA) and its adequate treatment rep

192 Patients with rheumatoid arthritis (RA) are at higher risk of developi

193 HBV reactivation (HBVr) among patients with rheumatoid arthritis (RA) are incomplete.

194 Current treatments for rheumatoid arthritis (RA) do not reverse underlying aber

195 Rheumatoid arthritis (RA) fibroblast-like synoviocytes (

196 Rheumatoid arthritis (RA) has been associated with endot

197 DNA methylation signatures in rheumatoid arthritis (RA) have been identified in fibrob

198 Genome-wide association studies of rheumatoid arthritis (RA) identified a susceptibility lo

199 d a large-scale MHC fine-mapping analysis of rheumatoid arthritis (RA) in a Japanese population (6,24

200 Pathogenic T cells in individuals with rheumatoid arthritis (RA) infiltrate non-lymphoid tissue

201 Rheumatoid arthritis (RA) is a chronic inflammatory cond

202 Rheumatoid arthritis (RA) is a chronic inflammatory cond

203 ABSTRACT: Rheumatoid arthritis (RA) is a chronic inflammatory cond

204 KEY POINTS: Rheumatoid arthritis (RA) is a chronic inflammatory cond

205 Rheumatoid arthritis (RA) is a heterogeneous, prevalent,

206 Sero-negative rheumatoid arthritis (RA) is a highly heterogeneous diso

207 Rheumatoid Arthritis (RA) is a multisystem disorder, whi

208 Rheumatoid arthritis (RA) is a progressive disease that

209 Rheumatoid arthritis (RA) is a severely debilitating chr

210 Rheumatoid arthritis (RA) is an inflammatory autoimmune

211 Rheumatoid arthritis (RA) is associated with amino acid

212 Rheumatoid arthritis (RA) is characterized by autoimmune

213 the increased risk of heart failure (HF) in rheumatoid arthritis (RA) is independent of ischemic hea

214 o suggest that autoimmunity in patients with rheumatoid arthritis (RA) is initiated outside the joint

215 The development of rheumatoid arthritis (RA) is linked to functional change

216 The etiology of rheumatoid arthritis (RA) is poorly understood, and 30%

217 revious studies suggest that pathogenesis of rheumatoid arthritis (RA) is similar in all affected joi

218 Rheumatoid arthritis (RA) is the most common inflammator

219 l of recombinant human TRAIL in experimental rheumatoid arthritis (RA) models.

220 rs in healthy donors (HDs) and patients with rheumatoid arthritis (RA) or systemic lupus erythematosu

221 o treat auto-immune related diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosu

222 Rheumatoid arthritis (RA) patients have been observed to

223 trullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) patients versus control patien

224 toantibodies (ACPA) coexist in the joints of rheumatoid arthritis (RA) patients where they probably c

225 uccinate is abundant in synovial fluids from rheumatoid arthritis (RA) patients, and these fluids eli

226 terns by indirect immunofluorescence for 859 rheumatoid arthritis (RA) patients.

227 r disease is a leading cause of morbidity in rheumatoid arthritis (RA) patients.

228 ed from pooled synovial fluid (SF) from four rheumatoid arthritis (RA) patients.

229 status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.

230 Recent metabolomics studies of Rheumatoid Arthritis (RA) reported few metabolites that

231 pirical data from a large-scale trans-ethnic rheumatoid arthritis (RA) study and showed that the func

232 When studies on rheumatoid arthritis (RA) that were made many decades ag

233 TNF-alpha is a major cytokine implicated in rheumatoid arthritis (RA), and its expression is regulat

234 er for clinical improvement in patients with rheumatoid arthritis (RA), and macrophages are reduced i

235 arget therapy is effective for patients with rheumatoid arthritis (RA), but long-term results of cont

236 Farming has been associated with rheumatoid arthritis (RA), but the role of pesticides is

237 In rheumatoid arthritis (RA), cartilage and bone matrix are

238 In rheumatoid arthritis (RA), chronic inflammation is thoug

239 code a "shared epitope" (SE) associated with rheumatoid arthritis (RA), especially more severe cyclic

240 Disease activity of rheumatoid arthritis (RA), evaluated as Disease Activity

241 In rheumatoid arthritis (RA), immunological triggers at muc

242 ts, and identified significant enrichment in rheumatoid arthritis (RA), kidney function, and adult he

243 tified over 100 genetic loci associated with rheumatoid arthritis (RA), our ability to translate thes

244 s specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), os

245 In patients with rheumatoid arthritis (RA), T cell aging occurs premature

246 In rheumatoid arthritis (RA), the proliferation of fibrobla

247 The mechanisms underlying rheumatoid arthritis (RA)-induced pain are still not ful

248 inhibitors) as agents for the management of rheumatoid arthritis (RA).

249 atologic disease parameters in patients with rheumatoid arthritis (RA).

250 nercept-methotrexate in patients with active rheumatoid arthritis (RA).

251 and T reg cells isolated from patients with rheumatoid arthritis (RA).

252 have a critical role in the pathogenesis of rheumatoid arthritis (RA).

253 is a central feature in the pathogenesis of rheumatoid arthritis (RA).

254 etermine the osteoclastogenic role of H4R in rheumatoid arthritis (RA).

255 major role in invasive joint destruction in rheumatoid arthritis (RA).

256 as investigated for new treatment options in rheumatoid arthritis (RA).

257 hort 46% were female; 71% had a diagnosis of Rheumatoid Arthritis (RA).

258 toimmune diseases: coeliac disease (CeD) and rheumatoid arthritis (RA).

259 tor (RF), are an important characteristic of rheumatoid arthritis (RA).

260 L) is critically involved in bone erosion of rheumatoid arthritis (RA).

261 spectively, in autoimmune diseases including rheumatoid arthritis (RA).

262 se1 in a chronic inflammatory joint disease, rheumatoid arthritis (RA).

263 is a proinflammatory cytokine implicated in rheumatoid arthritis (RA).

264 sclerosis, fibrosis, Alzheimer's disease and rheumatoid arthritis (RA).

265 s has been implicated in the pathogenesis of rheumatoid arthritis (RA).

266 riasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA).

267 ) are present in two-thirds of patients with rheumatoid arthritis (RA).

268 eptor mediated inflammatory signaling in the rheumatoid arthritis (RA).

269 and maintenance of autoimmune diseases like rheumatoid arthritis (RA).

270 plement is implicated in the pathogenesis of rheumatoid arthritis (RA); elevated levels of complement

271 the chronic inflammatory autoimmune disease rheumatoid arthritis (RA); however, controversial data a

272 cupation of farming has been associated with rheumatoid arthritis (RA); pesticides may account for th

273 control subjects (n = 76) and patients with rheumatoid arthritis (RA, n = 244).

274 x 10(-4)) and for 11 autoimmune diseases and rheumatoid arthritis (RA; P < 1 x 10(-3)).

275 Lung complications are a major cause of rheumatoid arthritis-related mortality.

276 ediates the beneficial actions of statins in rheumatoid arthritis remains of interest.

277 role of endogenous glucocorticoids (GCs) in rheumatoid arthritis remains unclear.

278 Importance: One-third of patients with rheumatoid arthritis show inadequate response to tumor n

279 cancers and increased risks for lung cancer, rheumatoid arthritis, Sjogren syndrome, and Raynaud synd

280 he development of autoimmunity, particularly rheumatoid arthritis, still needs extensive exploration.

281 For patients with newly diagnosed rheumatoid arthritis, strategies aimed at sustained remi

282 In the Wellcome Trust Rheumatoid Arthritis study, STAMS-identified modules wer

283 sk was higher when we used proxies of severe rheumatoid arthritis, such as ever having received daily

284 subset of late phase genes was expressed in rheumatoid arthritis synovial macrophages, confirming th

285 sue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutr

286 Antagonizing IL-1beta with Anakinra, a rheumatoid arthritis therapeutic, prevented detrusor pro

287 ritical for the induction and progression of rheumatoid arthritis through its pivotal role in the dev

288 Up to 40% of patients with rheumatoid arthritis treated with anti-tumour necrosis f

289 For patients with newly diagnosed rheumatoid arthritis, treatment aim is early, rapid, and

290 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to asse

291 ge 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, a

292 jacent to GAK, HLA-DRB5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disea

293 2 diabetes mellitus, multiple sclerosis, or rheumatoid arthritis) were included for comparison.

294 sms for immune-mediated disorders, including rheumatoid arthritis, were highly enriched for T-cell SE

295 r, reduced disease activity in patients with rheumatoid arthritis who had not previously received tre

296 A 54-year-old white woman with a history of rheumatoid arthritis who was taking glucocorticoids and

297 INTERPRETATION: In patients with active rheumatoid arthritis who were refractory or intolerant t

298 risk of serious infections in patients with rheumatoid arthritis who were treated with biological dr

299 patients (conducted between 2009-2012) with rheumatoid arthritis, with persistent disease activity (

300 ncluded patients who had been diagnosed with rheumatoid arthritis within 1 year before inclusion, wer